Large study finds positive yet mixed results from Akili’s digital therapeutic for kids with ADHD

By SharpBrains | February 25, 2020

__ Full pub­li­ca­tion of piv­otal tri­al data out­lines Akil­i’s case for FDA reg­u­la­tion (Mobi­Health­News): “A full tran­script of STARS-ADHD — the piv­otal tri­al of Akili Interactive’s video game-like pedi­atric atten­tion deficit treat­ment — has been pub­lished in The Lancet Dig­i­tal Health jour­nal, pro­vid­ing onlook­ers a clear view of data fuel­ing the dig­i­tal ther­a­peu­tic company’s pending…

Read More

Will digital therapeutics complement or replace stimulant medications to address inattention and “silent” cognitive issues?

By SharpBrains | January 29, 2020

___ Akili Inter­ac­tive: Dig­i­tal pedi­atric ADHD ther­a­peu­tic per­forms well with or with­out accom­pa­ny­ing stim­u­lant ther­a­py (Mobi­Health News): “Dig­i­tal ther­a­peu­tic com­pa­ny Akili Inter­ac­tive has announced the first results of an open-label, mul­ti­site pedi­atric ADHD tri­al pro­vid­ing some patients with the company’s video game-like treat­ment along­side a stim­u­lant med­ica­tion. Accord­ing to the com­pa­ny, both those who received…

Read More

Trend: Pharma industry warming up to digital therapeutics

By SharpBrains | August 22, 2019

Dig­i­tal ther­a­peu­tics have poten­tial but com­mer­cial suc­cess unproven (Van­tage): “Devel­op­ing drugs to treat dis­or­ders of the cen­tral ner­vous sys­tem is famous­ly fraught with dif­fi­cul­ty. Sev­er­al com­pa­nies, includ­ing Pear Ther­a­peu­tics and Dthera, are tak­ing a wild­ly dif­fer­ent approach: dig­i­tal ther­a­peu­tics. These are pieces of soft­ware designed to treat dis­ease that are reg­u­lat­ed, pre­scribed and even paid…

Read More